Annuaire de la recherche en pneumologie
| Nom du Laboratoire | Institut pour l'avancée des biosciences |
|---|---|
| N° d'équipe | INSERM U1209 Equipe Epissage des ARN signalisation cellulaire et réponse aux thérapies |
| Nom du directeur du laboratoire | HAINAUT Pierre |
| Nom du responsable | Pr EYMIN Béatrice |
| Courriel du responsable | beatrice.eymin@univ-grenoble-alpes.fr |
| Contacts principaux | Contacts principaux : Béatrice EYMIN beatrice.eymin@univ-grenoble-alpes.fr Sylvie GAZZERI sylvie.gazzeri@univ-grenoble-alpes.fr Anne-Claire TOFFART AToffart@chu-grenoble.fr |
| Adresse | Site Santé, Allée des Alpes |
| CP | 38700 |
| Ville | La Tronche |
| Pays | France |
| Téléphone | 0476549476 |
| Fax | |
| Site internet | https://iab.univ-grenoble-alpes.fr |
| Mots clés | Cancer du poumon-Epissage des ARN-résistance au traitement-signalisation |
| Résumé | Pre-mRNA alternative splicing controls gene expression and proteome diversity. Cancer cells often exhibit abnormal patterns of mRNA splice variants and an increasing number of studies now report deregulated expression as well as mutations of pre-mRNA splicing factors in tumors. However, the role of these alterations on tumor development and response to therapy remains largely unknown. These recent years, our team showed that deregulation of splicing factors of the SR family and alteration of specific splicing patterns contribute to lung cancer progression and resistance to chimiotherapy and targeted therapies (RTK). Our working strategies combine in vitro, in vivo and in situ studies as well as large scale transcriptomic analyses thanks to collaborative networks already established. A better understanding of the role played by SR proteins and splicing variants in response to treatment should identify new therapeutic targets and innovative strategies to overcome resistance, one of the major challenge in lung cancer therapeutics. |
| Axe principal | interplay between SR proteins and DNA damage response, altered mRNA splicing and resistance to chemotherapy and targeted therapies in lung cancer |
